BeiGene
2025.01.20
09:36
The Hong Kong stock biopharmaceutical sector rose in early trading, with WuXi AppTec (02359.HK) rising more than 5%, WuXi Biologics (02269.HK) rising more than 4%, BeiGene (06160.HK), Tiger Pharmaceuticals (03347.HK) and others following suit.
2025.01.14
09:22
Hong Kong stocks opened: Hang Seng Index opened 0.15% higher, Hang Seng Technology Index opened 0.14% higher
Hong Kong stocks opened, with the Hang Seng Index opening 0.15% higher and the Hang Seng Technology Index opening 0.14% higher. BeiGene and WuXi Biologics rose more than 3%.
2025.01.07
10:04
Hong Kong-listed pharmaceutical stocks fell, with Shandong Xinhua Pharmaceutical falling more than 5%
Hong Kong-listed pharmaceutical stocks fell, with Shandong Xinhua Pharmaceutical falling more than 5%, WuXi Biologics falling more than 4%, and WuXi AppTec, BeiGene, Junshi Biosciences and others following suit.
2024.12.31
17:28
US capital groups increase their holdings in Chinese tourism and real estate companies
According to information from the Hong Kong Stock Exchange's disclosure system, recently, the trillion-dollar asset management giant Capital Group has increased its holdings in Chinese tourism companies and real estate companies, betting on investment opportunities brought by a further rebound in the economy. In addition, Capital Group's first Asian flagship fund has a heavy position in Chinese Internet companies. China is the fund's largest market. Since October, Capital Group has increased its holdings in Huazhu Group. Since November, Capital Group has increased its holdings in Poly Property several times. In December, Capital Group also increased its holdings in Hong Kong-listed semiconductor leader ASM Pacific Technology Co., Ltd. Since October, Capital Group has also adjusted some of its holdings, reducing its holdings in Zai Lab, BeiGene, China Duty Free Group and other stocks. According to data, Capital Group is headquartered in Los Angeles, USA, and its latest management scale is about US$2.7 trillion. It has a history of 93 years and is best known for its long-term investment philosophy and investment model of co-management by multiple fund managers.
2024.12.30
10:01
Hong Kong-listed biopharmaceutical stocks rose during the session, with InnoCare Pharma (02359.HK) and WuXi AppTec (02359.HK) both rising by more than 4%, Tiger Pharmaceuticals (03347.HK) rising by more than 3.5%, GenScript Biotech (01548.HK), Zai Lab (09688.HK), WuXi Biologics (02269.HK), and BeiGene (06160.HK) all rising by more than 2%.
2024.12.19
09:24
Many stocks in the Hong Kong biopharmaceutical sector opened lower, with WuXi AppTec (02359.HK) opening down 2.78%, WuXi Biologics (02269.HK) opening down 2.77%, Tiger Pharmaceuticals (03347.HK), BeiGene (06160.HK) and others following suit.
2024.12.13
08:30
CSPC Pharmaceutical Group: Signed an exclusive licensing agreement with BeiGene for SYH2039
On December 13, CSPC Pharmaceutical Group announced on the Hong Kong Stock Exchange that it has entered into an exclusive licensing agreement with BeiGene for the global development, manufacturing and commercialization of the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039) and any subsequent pharmaceutical products consisting of or containing the compound.
2024.12.05
09:46
Hong Kong stocks' innovative drug sector fell in early trading, with BeiGene falling more than 3%
The Hong Kong stock market's innovative drug sector fell in early trading, with BeiGene falling more than 3%, WuXi Biologics falling more than 2%, China Biologic Products, Innovent Biologics, Shanghai Pharmaceuticals and others falling.
2024.12.04
18:37
BeiGene: HHLR Fund, LP and its affiliated entities reduced their stake to 9.02%
BeiGene announced that its shareholders HHLR Fund, LP, Hillhouse BGN Holdings Limited and YHG Investment, LP reduced their holdings of the company's overseas tradable shares by a total of 21.9973 million shares through centralized bidding and block trading from June 8, 2023 to December 2, 2024. After this equity change, the number of shares held by HHLR Fund, LP and its affiliated entities decreased from 147 million shares to 125 million shares, and the proportion of shares held in the total number of issued shares of the company decreased from 10.61% to 9.02%. After this equity change, the company's status of having no controlling shareholder and no actual controller has not changed.
2024.10.25
08:06
BeiGene Greater China CCO said to be under investigation
Asia Tech Wire (Oct 25) -- Chinese biotech firm BeiGene's (BGNE:NASDAQ; 6160.HK) chief commercial officer for Greater China, Eva Yin, is said to be under investigation by Chinese regulators, according to recent market rumors.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Southwest Airlines CEO: Although Boeing still has a lot of work to do, they seem to be moving in a good direction and we are more optimistic.

2025-01-31

White House Press Secretary Levitt: Details about the Nvidia meeting are still unclear.

2025-02-01

Apple (AAPL.O) said the Apple Pay outage has been resolved.

2025-01-29

Jefferies: Raised Meta Platforms (META.O) price target from $715 to $810.

2025-01-30

Sam Altman, founder and CEO of OpenAI: OpenAI will develop specialized hardware for AI.

2025-02-03

ASIA TECH WIRE

Grasp technology trends

Download